Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
ESMO Open
|
October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
N Peled, A Tufman, L V Sequist, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
J Hoffman-Censits, M Tsiatas, P M-H Chang, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
Actas Urologicas Espanolas
|
February 14, 2025
Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review
A A Grosso, A Cadenar, S Pillozzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
F Rossari, D Lavacchi, E Alimenti, et al.
ESMO Open
|
July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)
G Roviello, F Ciccimarra, F Urabe, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
International Journal of Cancer
|
September 1, 2016
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
F Pietrantonio, M Caporale, F Morano, et al.
ESMO Open
|
October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
N Peled, A Tufman, L V Sequist, et al.
ESMO Open
|
June 13, 2022
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
A Boccaccino, B Borelli, R Intini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis
J Hoffman-Censits, M Tsiatas, P M-H Chang, et al.
ESMO Open
|
July 16, 2025
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
V Daprà, A Gandini, F Schietroma, et al.
Actas Urologicas Espanolas
|
February 14, 2025
Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review
A A Grosso, A Cadenar, S Pillozzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2016
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
F Pietrantonio, R Miceli, L Rimassa, et al.
ESMO Open
|
November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis
G Trovato, D Rossini, A Guidolin, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
F Rossari, D Lavacchi, E Alimenti, et al.
ESMO Open
|
July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)
G Roviello, F Ciccimarra, F Urabe, et al.
Page
of 3